Sponsors (50)
The bill provides multi‑year, predictable federal funding to improve type 1 diabetes research and care (helping patients and health systems) in exchange for about $800 million in additional federal spending over five years.
People with type 1 diabetes will receive sustained federal funding ($160 million per year, 2026–2030) that supports improved treatments, care, and programs.
Researchers, hospitals, and health systems gain predictable multi‑year funding, enabling longer-term studies, program planning, and continuity of diabetes research and care initiatives.
Taxpayers and the federal budget will absorb roughly $800 million in additional spending over five years to pay for the program, which could crowd out other priorities or increase deficits if not offset.
Based on analysis of 2 sections of legislative text.
Authorizes $160 million per year for FY2026–2030 for the Special Diabetes Program for Type I diabetes, with funds available until expended.
Official title: To extend funding for Special Diabetes Programs for Type I diabetes.
Introduced September 18, 2025 by Diana DeGette · Last progress September 18, 2025
Provides five years of new authorized funding for the Special Diabetes Program for Type I diabetes, authorizing $160 million per year for fiscal years 2026 through 2030 with the funds to remain available until expended. It amends the Public Health Service Act to add the new authorization and makes a minor punctuation adjustment to accommodate the new paragraph. The change is an authorization (not an appropriation) that establishes a statutory funding level and availability period for the program supporting Type 1 diabetes research, prevention, and care activities.